Atara Biotherapeutics (ATRA) Assets Average (2014 - 2026)

Atara Biotherapeutics has reported Assets Average for 13 years, with the latest figure at $20.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 76.49% year-over-year to $20.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.1 million (down 76.49% YoY), and the FY2025 full-year result was $64.7 million, down 52.9% from the prior year.
• Assets Average for Q1 2026 stood at $20.1 million, down from $25.2 million in the prior quarter.
• The five-year high for Assets Average was $432.7 million in Q1 2022, with the low at $20.1 million in Q1 2026.
• Historically, Assets Average has averaged $200.5 million across 5 years, with a median of $165.4 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average declined 11.28% — and 2025, when it plunged 79.98%.
• Atara Biotherapeutics' Assets Average stood at $372.4 million in 2022, then slumped by 52.43% to $177.1 million in 2023, then retreated by 28.93% to $125.9 million in 2024, then sank by 79.98% to $25.2 million in 2025, then slipped by 20.18% to $20.1 million in 2026.
• The last three Assets Average figures came in at $20.1 million (Q1 2026), $25.2 million (Q4 2025), and $33.5 million (Q3 2025), per Business Quant data.